Select a medication above to begin.
oliban Indien
boswellia (Boswellia serrata)
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- allergic rhinitis [Insufficient Evidence]
- Alzheimer dz [Insufficient Evidence]
- arthralgia, aromatase inhibitor-induced [Insufficient Evidence]
- asthma [Insufficient Evidence]
- brain tumor [Insufficient Evidence]
- cluster headache [Insufficient Evidence]
- COVID-19 [Insufficient Evidence]
- Crohn dz [Insufficient Evidence]
- diabetes mellitus [Insufficient Evidence]
- diarrhea [Insufficient Evidence]
- dysmenorrhea [Insufficient Evidence]
- exercise-induced muscle soreness [Insufficient Evidence]
- IBS [Insufficient Evidence]
- knee pain [Insufficient Evidence]
- menorrhagia [Insufficient Evidence]
- microscopic colitis [Insufficient Evidence]
- osteoarthritis [Possibly Effective]
- pain, acute [Insufficient Evidence]
- pharyngitis [Insufficient Evidence]
- prostatitis and chronic pelvic pain syndrome [Insufficient Evidence]
- rheumatoid arthritis [Insufficient Evidence]
- rhinosinusitis [Insufficient Evidence]
- stroke [Insufficient Evidence]
- traumatic brain injury [Insufficient Evidence]
- ulcerative colitis [Insufficient Evidence]
- urinary incontinence [Insufficient Evidence]
- UTI [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
Alzheimer dz
- [Insufficient Evidence]
- Dose: 1200 mg PO qd
arthralgia, aromatase inhibitor-induced
- [Insufficient Evidence]
- Dose: 40 mg PO qd
asthma
- [Insufficient Evidence]
- Dose: 300 mg PO tid
brain tumor
- [Insufficient Evidence]
- Dose: 1400 mg PO tid
COVID-19
- [Insufficient Evidence]
- Dose: 300 mg PO bid; Info: used w/ licorice and standard tx
diabetes mellitus
- [Insufficient Evidence]
- Dose: 400 mg PO bid; Info: give after meals
diarrhea
- [Insufficient Evidence]
- Dose: 250 mg PO bid
dysmenorrhea
- [Insufficient Evidence]
- Dose: 10 mg boswellic acid PO x1; Start: on day of menstruation; Info: used w/ turmeric
exercise-induced muscle soreness
- [Insufficient Evidence]
- Dose: 10 mg boswellic acid PO x1; Info: used w/ turmeric
IBS
- [Insufficient Evidence]
- Dose: 250 mg PO qd
menorrhagia
- [Insufficient Evidence]
- Dose: 300 mg PO tid x7 days
microscopic colitis
- [Insufficient Evidence]
- Dose: 400 mg PO tid
osteoarthritis
- [Possibly Effective]
- Dose: 100-1000 mg/day PO divided qd-tid; Alt: 7.2 mg boswellic acid PO qd
pain, acute
- [Insufficient Evidence]
- Dose: 10 mg boswellic acid PO qd; Info: used w/ turmeric
rheumatoid arthritis
- [Insufficient Evidence]
- Dose: 200 mg PO tid
rhinosinusitis
- [Insufficient Evidence]
- Dose: 125-250 mg PO qd; Info: for pts 12 yo and older
stroke
- [Insufficient Evidence]
- Dose: 800 mg boswellic acid PO tid
traumatic brain injury
- [Insufficient Evidence]
- Dose: 360-400 mg PO tid; Info: used w/ or w/o ginger
ulcerative colitis
- [Insufficient Evidence]
- Dose: 300-350 mg PO tid; Alt: 250 mg PO qd
urinary incontinence
- [Insufficient Evidence]
- Dose: 300 mg PO bid
UTI
- [Insufficient Evidence]
- Dose: 200 mg PO qd
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.